Guru Kashi University
The management of psychiatric disorders such as schizophrenia, bipolar disorder, and depression often requires long-term administration of psychotropic medications. Despite their therapeutic efficacy, oral and parenteral dosage forms of antipsychotic drugs frequently face challenges including poor patient compliance, extensive first-pass metabolism, dose-dependent side effects, and fluctuating plasma drug concentrations. These factors significantly compromise therapeutic outcomes and increase relapse rates in patients requiring chronic treatment. Transdermal Drug Delivery Systems (TDDS) have emerged as an advanced, non-invasive approach to overcome these limitations by providing controlled, sustained, and site-specific delivery of active pharmaceutical ingredients through the skin into systemic circulation. TDDS offer several pharmacokinetic and pharmacodynamic advantages over conventional routes. They bypass hepatic first-pass metabolism, reduce gastrointestinal irritation, and maintain steady-state plasma drug levels, thereby minimizing dose-related adverse effects and improving patient adherence. The application of TDDS in psychopharmacotherapy is particularly promising for atypical antipsychotics such as risperidone, olanzapine, quetiapine, and clozapine, which are characterized by narrow therapeutic indices and require consistent plasma concentrations for efficacy. The use of polymers like Eudragit RL100 and RS100, in combination with plasticizers and permeation enhancers such as surfactants (Span 20, SLS) and natural oils (olive, jojoba, groundnut), enables the fabrication of stable, flexible, and biocompatible transdermal patches capable of achieving optimal flux across the stratum corneum. Recent advances in transdermal technology—including microneedles, iontophoresis, and nanocarrier-based systems—further enhance the permeability and bioavailability of psychotropic agents, offering alternatives to patients who are noncompliant or unable to tolerate oral medication. In this context, TDDS not only optimize therapeutic outcomes but also represent a paradigm shift in the delivery of central nervous system (CNS) drugs, providing sustained, safe, and patient-friendly management of psychotic disorders. The present review emphasizes the scientific basis, formulation design, evaluation parameters, and clinical significance of transdermal drug delivery systems for atypical antipsychotics, highlighting their transformative potential in modern psychopharmacology.
Schizophrenia is a chronic, debilitating psychiatric disorder that affects approximately 1% of the global population. Characterized by hallucinations, delusions, disorganized thought, and impaired social functioning, it demands lifelong pharmacological management. The cornerstone of treatment involves antipsychotic drugs—particularly atypical antipsychotics such as risperidone, olanzapine, clozapine, and quetiapine—that modulate dopaminergic and serotonergic neurotransmission in the central nervous system (CNS). While these medications have revolutionized psychiatric care, their clinical efficacy is often undermined by the limitations of conventional oral and parenteral dosage forms. Oral antipsychotics are associated with poor bioavailability due to extensive first-pass metabolism and variable gastrointestinal absorption. Moreover, their frequent dosing requirements, unpleasant side effects (such as extrapyramidal symptoms, metabolic disorders, and sedation), and delayed onset of action contribute to poor patient adherence. In schizophrenia, adherence is a critical determinant of therapeutic success—non-compliance rates often exceed 50%, leading to relapse, rehospitalization, and socio-economic burden. Parenteral long-acting injectables, while addressing compliance to some extent, present their own drawbacks including pain at the injection site, risk of infection, and lack of dose flexibility. Hence, there is an urgent need for a more patient-friendlier, reliable, and sustained approach to antipsychotic drug delivery. Transdermal Drug Delivery Systems (TDDS) present an innovative and non-invasive alternative that can effectively address these challenges. By delivering therapeutic agents through the skin into systemic circulation, TDDS bypass hepatic first-pass metabolism and gastrointestinal degradation, ensuring predictable pharmacokinetics. They maintain a steady plasma drug concentration within the therapeutic window for an extended duration, thereby minimizing peak–trough fluctuations and dose-related adverse effects. This sustained-release property is particularly advantageous for psychotropic drugs, which require consistent levels in the CNS to maintain symptom control and prevent relapse. Furthermore, the non-invasive nature of transdermal systems enhances patient comfort and compliance, especially for individuals with cognitive or behavioral impairments who struggle with oral medication schedules. The ease of patch removal also allows for immediate discontinuation of therapy in case of adverse reactions, offering superior safety and dose control. Incorporating polymers like Eudragit RL100 and RS100, along with suitable plasticizers and permeation enhancers, enables the fabrication of patches with optimal mechanical strength, flexibility, and controlled drug release characteristics. In the context of schizophrenia management, TDDS can transform pharmacotherapy by providing sustained antipsychotic exposure, reducing systemic side effects, improving patient quality of life, and lowering healthcare costs. As research progresses, the integration of novel technologies such as microneedle-assisted delivery, iontophoresis, and nanocarrier-based systems further expands the potential of transdermal formulations to achieve precise, long-term, and patient-centric management of psychiatric disorders.
Mechanism of Transdermal Drug Delivery System
Transdermal Drug Delivery Systems (TDDS) are designed to transport therapeutic agents across the skin barrier into the systemic circulation, providing controlled and sustained plasma drug concentrations. The skin, though primarily a protective organ, can serve as an effective route for systemic drug administration when the formulation is optimized to overcome its physiological barriers. Understanding the mechanism of drug permeation through the skin is essential for the rational design of transdermal systems, particularly for psychotropic drugs that require consistent delivery over extended periods.
Structure of the Skin and Its Role in Permeation
The skin is composed of three primary layers:
Among these, the stratum corneum—comprising 10–20 layers of flattened, keratinized cells embedded in a lipid matrix—is the most critical barrier. It is often described as a “brick-and-mortar” structure, where the corneocytes act as bricks and the intercellular lipids form the mortar. The diffusion of a drug through this layer largely determines its transdermal absorption rate.
Pathways of Drug Permeation
Drugs can penetrate the skin via three main routes:
Transcellular (Intracellular) Route:
The drug diffuses directly through the corneocytes and the intercellular lipid domains. This pathway requires the drug to repeatedly partition between hydrophilic and lipophilic phases, making it suitable only for molecules with balanced lipophilicity (log P 1–3).
Intercellular Route:
The drug diffuses through the tortuous lipid matrix surrounding the corneocytes. This is the predominant pathway for most lipophilic drugs and depends on the lipid organization of the stratum corneum.
Trans appendageal (Shunt) Route:
The drug bypasses the stratum corneum via appendages such as hair follicles, sweat glands, and sebaceous glands. Although these appendages cover only about 0.1% of the total skin surface, they provide important pathways for ions, large molecules, and macromolecular drug delivery.
Driving Forces for Transdermal Permeation
Drug movement across the skin occurs mainly by passive diffusion, governed by Fick’s first law:
where J is the flux (amount of drug transported per unit area per unit time), D is the diffusion coefficient, and dC/dx is the concentration gradient across the skin. The steady-state flux (Jss) is directly proportional to the drug concentration in the formulation and inversely proportional to the thickness of the stratum corneum. Hence, maintaining a high concentration gradient across the skin is crucial for sustained permeation.
Factors Influencing Transdermal Drug Absorption
Several factors affect the rate and extent of transdermal drug delivery:
Advanced Mechanisms for Enhanced Permeation
To overcome the inherent resistance of the stratum corneum, various physical and biochemical enhancement techniques have been developed:
In an optimized TDDS, the drug is released from the polymeric matrix or reservoir, diffuses through the adhesive layer, penetrates the stratum corneum, and subsequently reaches the deeper epidermal and dermal layers before entering systemic circulation via dermal capillaries. The process can be summarized as:
This multi-step mechanism ensures continuous drug delivery over prolonged durations, minimizing plasma concentration fluctuations. For psychotropic medications like risperidone, such controlled transdermal transport ensures steady therapeutic levels, reduces side effects, and enhances adherence—key factors for effective schizophrenia management.
Formulation
The performance, stability, and therapeutic efficiency of a transdermal drug delivery system (TDDS) largely depend on its formulation components. Each component plays a specific role in determining the physicochemical characteristics of the patch, such as drug release rate, permeability, mechanical strength, and bioadhesive properties. For antipsychotic transdermal patches—particularly those containing risperidone—polymers, plasticizers, and permeation enhancers form the triad of key formulation constituents.
Polymers (Eudragit RL100 and Eudragit RS100)
Polymers serve as the backbone of the transdermal matrix or reservoir system, controlling both the drug release kinetics and patch integrity. In the present context, Eudragit RL100 and Eudragit RS100 are the most widely used copolymers for sustained-release transdermal applications.
Plasticizers
Plasticizers are essential additives that enhance the flexibility, mechanical strength, and elasticity of transdermal films. They reduce the brittleness of polymer matrices by intercalating between polymer chains and decreasing the glass transition temperature (Tg), which results in improved film formation and better handling characteristics.
Permeation Enhancers
The stratum corneum acts as the principal barrier to drug diffusion through the skin. Permeation enhancers are incorporated into TDDS formulations to temporarily modify the skin barrier, improving the rate and extent of drug permeation without causing irritation or irreversible damage.
Surfactant-Based Enhancers
Surfactants interact with the lipid bilayers of the stratum corneum, altering their structural organization and increasing drug diffusivity.
Natural Oils as Enhancers
Natural vegetable oils offer a safer alternative to synthetic surfactants due to their biodegradability, skin compatibility, and low irritation potential. They enhance permeation primarily by modifying lipid domains and hydrating the stratum corneum.
Comparative Effectiveness
Experimental findings have shown the following order of enhancement efficiency for risperidone TDDS:
Span 20 > Benzalkonium Chloride > SLS > Olive Oil > Groundnut Oil > Jojoba Oil.
Synergistic Role of Formulation Components
The optimal combination of Eudragit RL/RS polymers, di-n-butyl phthalate as plasticizer, and Span 20 or olive oil as permeation enhancer results in a stable, flexible, and efficient transdermal system. This synergy ensures:
|
Component Category |
Function in TDDS |
Common Examples |
Specific Role in Risperidone TDDS |
|
Polymers |
Form the structural matrix or reservoir for drug incorporation and control drug release rate |
Eudragit RL100, Eudragit RS100 |
Provide controlled and sustained drug release; RL100 increases permeability, RS100 offers prolonged release; combination ensures optimal steady-state plasma levels |
|
Plasticizers |
Enhance film flexibility, reduce brittleness, and improve mechanical strength |
Di-n-butyl phthalate, Propylene glycol, Triethyl citrate |
Di-n-butyl phthalate improves patch elasticity, adhesion, and smoothness without affecting release kinetics |
|
Permeation Enhancers (Synthetic) |
Increase drug diffusion across the stratum corneum by altering lipid structure or increasing solubility |
Span 20, SLS, Benzalkonium chloride |
Span 20 enhances risperidone flux (≈23.14 µg/cm²/h); Benzalkonium chloride improves drug partitioning; SLS enhances hydrophilic drug permeability |
|
Permeation Enhancers (Natural) |
Modify skin lipids and increase hydration to facilitate drug penetration |
Olive oil, Jojoba oil, Groundnut oil |
Olive oil (rich in oleic acid) most effective; jojoba and groundnut oils improve hydration and compatibility |
|
Adhesives |
Ensure intimate contact between the patch and skin surface |
Polyisobutylene, Silicone adhesive |
Maintain uniform adhesion for consistent delivery; prevent patch detachment during prolonged wear |
|
Backing Membrane |
Provide mechanical support and prevent drug loss from the patch’s upper surface |
Polyethylene terephthalate (PET), Aluminum foil |
Protects formulation, provides flexibility, and ensures occlusivity |
|
Release Liner |
Protects the adhesive layer before application |
Polyester film, Silicone-coated liner |
Prevents contamination and maintains patch integrity prior to use |
|
Solvents |
Aid in polymer dissolution and uniform dispersion of drug and excipients |
Ethanol, Methanol, Chloroform |
Facilitate homogeneous film casting and solvent evaporation during patch formation |
Recent Studies
Early foundational work and physicochemical determinants (1990s)
Foundational studies in the 1990s established the physicochemical rules governing transdermal delivery (molecular weight, log P, melting point) and compared reservoir vs. matrix designs for sustained release (e.g., controlled scopolamine release through EVA). Investigations also correlated drug–patch transfer with drug physicochemical properties and highlighted the critical role of solvent and polymer selection for reliable film formation. These early works provided the mechanistic basis for later antipsychotic TDDS development.
Chemical permeation enhancers and formulation strategies
Multiple studies evaluated chemical enhancers (surfactants, fatty acids, azones, solvents) and showed that enhancers can modify stratum corneum lipids or protein structure to increase flux. Comparative work demonstrated that some natural fatty acids/vegetable oils (oleic-rich oils) can be as effective as synthetic enhancers while offering better skin tolerability — an observation pursued for risperidone (olive, jojoba, groundnut oils) and other drugs. The dissertation cites experiments where non-ionic surfactants (e.g., Span 20) and certain vegetable oils significantly increased transdermal flux.
Assisted physical enhancement technologies (iontophoresis, sonophoresis, electroporation, microneedles)
Research from the 2000s onward demonstrated that physical enhancement methods expand the range of deliverable molecules beyond the traditional “rules.” Iontophoresis, sonophoresis, and electroporation were shown to increase delivery of charged and larger molecules, and early clinical/experimental systems (e.g., iontophoretic lithium) illustrated therapeutic feasibility. More recent work (late 2010s–2021) emphasises microneedle (MN) approaches (poke-and-patch, dissolving MNs) as a minimally invasive method to overcome the stratum corneum for improved delivery and patient acceptability. These advances are particularly relevant for psychotropics that otherwise have limited passive skin permeability.
TDDS for psychotropic drugs — preclinical and early clinical evidence
Several groups explored TDDS specifically for antipsychotics and related psychotropics. Notable examples discussed in the chapter include: formulation and in vivo evaluation of clozapine and quetiapine transdermal systems showing improved bioavailability and sustained flux; iontophoretic or reservoir approaches for drugs like haloperidol; and formulation optimization studies demonstrating significant enhancement of bioavailability vs. oral formulations. The dissertation highlights that transdermal clozapine and quetiapine patches (2020–2021) achieved substantial flux and stability, and in some cases multi-fold bioavailability improvements.
Secuado® (asenapine) — an important clinical example
The literature review points to asenapine transdermal system (Secuado®) as a prominent successful translation of TDDS for schizophrenia: pivotal phase-3 data showed once-daily patches reduced psychotic symptoms with tolerability comparable to other routes. Secuado is used as an exemplar that transdermal psychotropic therapy can reach regulatory approval and clinical practice, reinforcing the potential for other atypical antipsychotics.
Quality-by-Design (QbD), DoE and formulation optimization trends (2010s–2021)
Recent formulation studies increasingly apply Quality-by-Design (QbD) and statistical experimental design (e.g., Box–Behnken) to optimize polymer ratios, plasticizer levels, and enhancer concentrations. This systematic approach has produced reproducible patches with predictable flux, tensile strength, and stability (several 2020–2021 studies on quetiapine and clozapine are cited). Such methodologies are now standard for robust TDDS development and are recommended for risperidone systems.
Comparative findings and common formulation lessons
Across studies cited, common conclusions emerge: (a) polymer selection and polymer grade blending (e.g., mixed Eudragit grades) enable tuning of release; (b) plasticizer concentration critically affects film flexibility and handling; (c) non-ionic surfactants and select vegetable oils provide effective enhancement with lower irritation risk; and (d) in vitro permeation data must be supported by in vivo pharmacokinetics and pharmacodynamics to confirm sustained therapeutic effect and safety. The dissertation’s risperidone work follows and confirms these lessons, selecting ERL/ERS blends with DBP plasticizer and olive oil/Span 20 as top enhancers.
Gaps, safety considerations and translational challenges
Despite promising preclinical and some clinical data, the literature emphasizes challenges: ensuring skin safety during chronic application, maintaining consistent adhesion and flux under real-world conditions, addressing dose flexibility, and meeting regulatory expectations for long-term stability and biocompatibility. The review in Chapter 4 stresses that for antipsychotics — where long-term therapy and variable patient populations matter — these translational hurdles must be addressed by rigorous skin irritation testing, stability studies, and appropriately powered clinical trials.
Emerging Technologies for Transdermal Delivery
Microneedles (MNs)
Microneedles are arrays of microscopic needles (typically 50–900 µm long) that painlessly breach the stratum corneum to create transient microchannels enabling accelerated delivery of small molecules, peptides, and even nanoparticles. There are several MN types: solid (poke-and-patch), coated, dissolving, and hollow. For psychotropic drugs that are otherwise marginal for passive transdermal transport (due to size, lipophilicity, or dose), MNs provide a minimally invasive route that preserves patient comfort and enables rapid onset or controlled prolonged delivery depending on MN design.
Advantages: rapid enhancement of permeability without significant pain; precise dosing with dissolving/coated MNs; compatibility with outpatient use.
Limitations: manufacturing complexity, sterility concerns, and regulatory considerations for a device–drug combination.
Relevance to antipsychotics: MNs can enable therapeutic fluxes for borderline molecules (e.g., higher dose atypicals) and allow lower-formulation reliance on harsh chemical enhancers.
Iontophoresis
Iontophoresis uses a low-intensity electric current to drive charged drug ions across the skin. It is highly controllable — current magnitude and duration directly modulate delivered dose — and reversible (delivery stops when current is off).
Advantages: on-demand and programmable dosing; enhanced delivery of ionizable drugs; avoidance of chemical enhancers.
Limitations: requires a power source and a controlled device, potential local irritation or electrode-site reactions, and not ideal for long continuous wear unless patient-friendly device form factors are designed.
Relevance to antipsychotics: drugs that can be formulated as ionizable salts (or prodrugs) could be delivered episodically or as maintenance with wearable iontophoretic patches.
Liposomal and Nanocarrier-Based Patches
Nanocarriers (liposomes, niosomes, solid lipid nanoparticles) enhance drug partitioning into and through the stratum corneum by improving solubility, protecting labile drugs, and providing sustained release profiles. Incorporated within a patch matrix, these carriers can modulate release kinetics and target skin appendages (hair follicles) as reservoirs.
Advantages: improved drug stability and controlled release; potential for reduced irritation versus chemical penetration enhancers.
Limitations: formulation complexity, potential scale-up and stability challenges, and regulatory scrutiny of nanoparticulate carriers.
Relevance to antipsychotics: nanocarriers can be used to increase the local partitioning of lipophilic antipsychotics into the stratum corneum and sustain systemic flux without high concentrations of free enhancers.
Hybrid Approaches
Combining physical techniques (MNs or iontophoresis) with chemical enhancers or nanocarriers offers a synergistic approach: for example, MNs followed by a nanocarrier patch can permit both a rapid loading phase (through MN-created channels) and a prolonged maintenance phase from the patch reservoir.
Clinical Efficacy & Patient Compliance
Pharmacokinetic advantages and therapeutic implications
Transdermal systems can flatten peak–trough fluctuations, prolong mean residence time (MRT), and reduce peak concentration-related adverse effects. The uploaded risperidone dissertation reported TDDS achieving sustained exposure with a lower Cmax versus oral formulation (Cmax_TDDS ≈ 129.6 ng/mL vs marketed oral ≈ 256.7 ng/mL), with a slower elimination and longer MRT — hallmarks of sustained-release delivery that can reduce dose-dependent side effects while maintaining efficacy.
Demonstrated efficacy in preclinical and early clinical work
Preclinical pharmacodynamic tests (rotarod, grip strength, behavioral assays) in rodents/rabbits cited in the literature and the dissertation showed comparable tranquilizing/sedative effects between optimized TDDS and oral formulations at sustained exposures, indicating the potential for clinical equivalence with fewer side effects. Clinical translation is exemplified by the asenapine transdermal system (Secuado®), which demonstrated efficacy and tolerability in phase-3 trials, confirming that transdermal psychopharmacotherapy can reach regulatory approval and clinical use.
Patient compliance and real-world advantages
Collectively, these factors address major drivers of relapse (non-adherence) in schizophrenia, and empirical studies suggest TDDS can meaningfully lower relapse risk when consistent therapeutic exposure is maintained. However, long-term adherence depends on patch comfort, adhesion reliability, and absence of local skin reactions.
Future Perspectives and Challenges
Opportunities
Key challenges
CONCLUSION
Newer atypical antipsychotics like olanzapine and risperidone are safer and more effective for treating psychosis. To improve therapy and reduce side effects, transdermal drug delivery systems (TDDS) were developed using Eudragit-based matrix patches. The study evaluated various permeation enhancers (surfactants: BC, SLS, Span 20; and vegetable oils: olive, jojoba, groundnut) for their effect on drug permeation. For risperidone, batch RE3 (ERL 100: ERS100 3:2, 20% risperidone, 20% dibutyl phthalate, 10% olive oil) showed sustained release for 3 days at therapeutic flux. For olanzapine, batch OD3 (ERL 100: ERS100 3:2, 20% olanzapine, 30% dibutyl phthalate, 10% Span 20) demonstrated effective sustained release. The TDDS formulations enhanced bioavailability, allowed low-maintenance dosing, and improved patient compliance compared to oral therapy. Pharmacodynamic and pharmacokinetic studies in animals support their efficacy, and these formulations have potential for commercial scale-up, offering new therapeutic options for psychotic patients.
REFERENCE
Dr. Devinder Maheshwari*, Ankit Kumar, Advances in Transdermal Drug Delivery Systems for Atypical Antipsychotics: Formulation Strategies, Optimization, and Therapeutic Perspectives, Int. J. Sci. R. Tech., 2025, 2 (11), 494-504. https://doi.org/10.5281/zenodo.17640330
10.5281/zenodo.17640330
